The Health from Portugal (HfPT) project is a mobilising agenda for industrial innovation in the health sector that aims to be the first materialisation of the Health Development Plan (HDP), boosting its objectives of activating and accelerating the structural transformation of the Portuguese economy, speeding up recovery from the crisis and responding to important opportunities on a national, European and global scale.
With this ambition, the PDS will strengthen the country's specialisation profile in high value-added health activities and its international recognition, pursuing the PDS's ambitious objectives and targets in terms of investment in R&D, the economic value of knowledge, innovation, skilled employment and aligned and embedded exports
Neutroplast is involved in several projects on this agenda, with an emphasis on:
- The optimisation of medical devices for monitoring medication adherence previously developed in other Neutroplast projects (Gloria, Dosea and Smart-Health-4-All): SmartCap and SmartLabel. These devices are in the final stages of development and have a TLR of 5/6. The aim of this sub-project is to optimise the devices and the software, improve some features and validate the devices in different scenarios, so that they can be presented to the market. It is also intended, at an early stage, to carry out a study of its design, making it more inclusive.
- Participation with the integration of intelligent packaging in the development of a system for the distribution and dispensing of medicines between different locations with distribution monitoring throughout the process.
- Development of mechanisms to measure the degradation of medicines, based on data from the environment outside the packaging as well as inside. To this end, Neutroplast, together with FCT, will develop packaging with biosensors to assess changes in the chemical environment inside the packaging. This smartpackaging will communicate with the overall solution, which will be a device in which sensors and electronic components will be integrated to acquire, process and send data.
- In the chronic disease management platform (CDMP), Neutroplast will contribute medical devices for monitoring adherence and compliance with medication for chronic polymedicated people, so that treatments can be monitored.
Co-financed by: Plano de Recuperação e Resiliência; Next Generation EU
Duration: 01/11/2021 - 31/12/2025